NCT03559166

First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis

A Phase Ia/Ib, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BLD-2660 in Healthy Volunteers and Patients With Lung Fibrosis or Liver Fibrosis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 88 (actual)
• Sponsor: Blade Therapeutics · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

First in Human single ascending dose followed by multiple ascending doses in healthy volunteers.

Conditions

• Fibrosis

Interventions

Type	Name	Description
DRUG	BLD-2660	Randomized to active product or placebo

Timeline

• Start date: 2018-07-11
• Primary completion: 2019-10-04
• Completion: 2019-10-04
• First posted: 2018-06-18
• Last updated: 2020-03-19

Locations

1 site across 1 country: Australia